BioCentury
ARTICLE | Clinical News

CNDO-109: Phase I final data

January 9, 2012 8:00 AM UTC

Final data from a Phase I trial showed that 3 of 5 evaluable patients experienced a longer subsequent complete response after receiving a single IV infusion of CNDO-109 tumor-primed NK cells compared ...